Biosenic (FRA:BT1) Institutional Ownership : 0.43% (As of Apr. 29, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Biosenic Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biosenic's institutional ownership is 0.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biosenic's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biosenic's Float Percentage Of Total Shares Outstanding is 0.00%.

Biosenic Institutional Ownership Historical Data

The historical data trend for Biosenic's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Institutional Ownership Chart

Biosenic Historical Data

The historical data trend for Biosenic can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.04	0.04	0.04	0.12	0.12	0.03	0.03	0.03	0.43	0.43

Biosenic Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biosenic (FRA:BT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (FRA:BT1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (FRA:BT1) Headlines

No Headlines